Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine PET Imaging of Colorectal Cancer
NCT03275974Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2021
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of L-[5-11C]-glutamine and Florilglutamic acid F-18 in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Positron Emission Tomography imaging, Pharmacokinetic rate constants for 11C-Glutamine and 18F-FSPG and 1 more. Started Apr 2021; status: terminated.
02
Drugs
L-[5-11C]-glutamineFlorilglutamic acid F-18
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03275974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275974.